As technological advancements allow for new and innovative ways to improve healthcare delivery, hospitals are increasingly investing in the development of in-house technologies such as laboratory developed tests (LDTs), telemedicine systems, and clinical decision support software. The functionality of these technologies may render them subject to regulation by the US Food and Drug Administration (FDA). Hospitals will need to understand whether and how FDA policies apply to their products.
Topics will include:
For more information, please contact Talia Baghdoyan at +1.202.739.5283 or firstname.lastname@example.org.